Research programme: antibody targeted amanitin conjugates - Heidelberg Pharma Research

Drug Profile

Research programme: antibody targeted amanitin conjugates - Heidelberg Pharma Research

Alternative Names: anti-CD19-amanitin conjugate; anti-CD269-amanitin conjugate; ATACs - Heidelberg Pharma Research/Roche; BCMA-amanitin conjugate; CD 19 - ATAC; HDP-101; HDP-101-ATAC

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma Research; WILEX AG
  • Class Drug conjugates; Immunotoxins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Multiple myeloma; Solid tumours

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 20 Sep 2017 Heidelberg Pharma plans a phase I trial for Multiple myeloma by the end of 2018
  • 05 Apr 2017 Pharmacokinetics and pharmacodynamics data from a preclinical study in Solid tumours presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top